Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · IEX Real-Time Price · USD
15.16
+0.03 (0.20%)
At close: Jul 19, 2024, 4:00 PM
15.23
+0.07 (0.46%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Gyre Therapeutics Employees
Gyre Therapeutics had 593 employees as of December 31, 2023. The number of employees increased by 586 or 8,371.43% compared to the previous year.
Employees
593
Change (1Y)
586
Growth (1Y)
8,371.43%
Revenue / Employee
$237,137
Profits / Employee
-$144,454
Market Cap
1.30B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 593 | 586 | 8,371.43% |
Dec 31, 2022 | 7 | -38 | -84.44% |
Dec 31, 2021 | 45 | -11 | -19.64% |
Dec 31, 2020 | 56 | 22 | 64.71% |
Dec 31, 2019 | 34 | 13 | 61.90% |
Dec 31, 2018 | 21 | 8 | 61.54% |
Dec 31, 2017 | 13 | 3 | 30.00% |
Dec 31, 2016 | 10 | -9 | -47.37% |
Dec 31, 2015 | 19 | 0 | - |
Dec 31, 2014 | 19 | -21 | -52.50% |
Dec 31, 2013 | 40 | 0 | - |
Dec 31, 2012 | 40 | -102 | -71.83% |
Dec 31, 2011 | 142 | 10 | 7.58% |
Dec 31, 2010 | 132 | 16 | 13.79% |
Dec 31, 2009 | 116 | 2 | 1.75% |
Dec 31, 2008 | 114 | 10 | 9.62% |
Dec 31, 2007 | 104 | 15 | 16.85% |
Dec 31, 2006 | 89 | 11 | 14.10% |
Dec 31, 2005 | 78 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Omnicell | 3,650 |
Phreesia | 1,438 |
ANI Pharmaceuticals | 642 |
Arcus Biosciences | 577 |
Immatics | 535 |
Sana Biotechnology | 328 |
Nurix Therapeutics | 284 |
Ardelyx | 267 |
GYRE News
- 19 days ago - Gyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia - GlobeNewsWire
- 4 weeks ago - Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology - GlobeNewsWire
- 7 weeks ago - Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire
- 7 weeks ago - Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum - GlobeNewsWire
- 5 months ago - INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire